Arrowhead Pharmaceuticals, Inc. (ARWR) Stock: Seeing Declines In Today’s Session

0

Arrowhead Pharmaceuticals, Inc. (ARWR) is working its way for to the bottom in the market in today’s trading session. The stock, focused on the biotech space, is currently priced at $18.05 after tumbling -5.35% so far today. As it relates to biotech stocks, there are several factors that have the ability to generate price movement in the market. News is one of the most common reasons for movement. Here are the recent stories relating to ARWR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-18-19 07:30AM Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Mar-11-19 07:30AM Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
02:25AM Here’s Why Arrowhead Pharmaceuticals Gained 38.2% in February
Mar-07-19 08:01AM Does Arrowhead Pharmaceuticals, Inc.s (NASDAQ:ARWR) CEO Salary Reflect Performance?
Mar-01-19 07:30AM Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences

Nonetheless, any time investors are making an investing decision, investors should look at far more than just news, especially in the generally speculative biotech sector. Here’s what’s happening with Arrowhead Pharmaceuticals, Inc..

Recent Movement From ARWR

Although a single session decline, like what we’re seeing from Arrowhead Pharmaceuticals, Inc. might make some investors fearful, that by itself should not be the reason for a decision to, or not to, buy a company’s stock. It is always important to look at trends for a period longer than a single trading session. When it comes to ARWR, here are the returns on investment that investors have experienced:

  • Past 7 Days – Over the past 5 trading sessions, ARWR has produced a change in price amounting to 2.80%.
  • Past Month – The return on investment from Arrowhead Pharmaceuticals, Inc. over the last 30 days works out to 5.36%.
  • Quarterly – Throughout the past 3 months, the stock has produced a return on investment that comes to 38.89%
  • Bi-Annually – In the past 6 months, investors have seen a change that equates to 1.22% from the company.
  • This Year So Far – Since the open of this year ARWR has generated a return of 53.54%.
  • Full Year – Lastly, over the last full year, we have seen performance amounting to 165.23% out of ARWR. In this period, the stock has sold at a high price of -19.38% and a low price of 188.34%.

Ratios That Are Notable

Digging into a few ratios associated with a stock can give investors a look of how risky and/or rewarding a an investment option might be. Below are a few of the most important ratios to look at when digging into ARWR.

Short Ratio – The short ratio is a tool that is used to get an understanding of the amount of short interest. As the short ratio climbs, it means that more investors are expecting that the price of the stock is headed for declines. Throughout the sector, biotech stocks tend to carry a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the industry. Nonetheless, with regard to Arrowhead Pharmaceuticals, Inc., the stock’s short ratio comes to 9.31.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Basically, they measure the company’s abilities to pay its debts when they come due using quick assets or current assets. In the biotechnology sector, several companies rely heavily on the continuation of investor support, the quick and current ratios can seem upsetting. Nonetheless, some better companies in the biotechnology sector come with good quick and current ratios. In terms of ARWR, the quick and current ratios come to 1.80 and 1.80 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the price of shares. In the case of Arrowhead Pharmaceuticals, Inc., the book to share value ratio is 1.89.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the price of shares. Many clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to look into. As it relates to ARWR, the cash to share value ratio is 2.60.

How Analysts Feel About Arrowhead Pharmaceuticals, Inc.

Although it’s never a good idea to blindly follow the thoughts of analysts, it is a good idea to use their analysis in order to validate your own due diligence when it comes to making an investment decision in the biotechnology sector. Here are the recent moves that we have seen from analysts with regard to ARWR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-07-18 Upgrade B. Riley FBR Neutral → Buy $18 → $19
Sep-06-18 Reiterated Chardan Capital Markets Buy $17.50 → $24.50
Aug-08-18 Reiterated Cantor Fitzgerald Overweight $13 → $18
Jul-02-18 Reiterated Chardan Capital Markets Buy $9.50 → $16
May-09-18 Upgrade Cantor Fitzgerald Neutral → Overweight $13

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ARWR, here’s what we’re seeing:

  • Institutional Investors – Currently, institutions hold 63.60% of the company. However, it is important to mention that institutional ownership has seen a move in the amount of 5.55% in the past quarter.
  • Insiders – When it comes to insiders, members of the management team and others close to ARWR currently own 4.40% of the company. Insider ownership of the company has changed in the amount of -24.89% in the past quarter.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 93.85M shares of Arrowhead Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ARWR has a float of 85.86M.

It’s also important to dig into the short float. Think about it, when a large percentage of the float available for trading is shorted, the overall opinion in the market is that the stock is going to fall. As far as ARWR, the percentage of the float that is currently being sold short is 18.94%. Most investors would say that a concerning short percent of the float is anything over 40%. Through my work, I’ve seen that any short percent of the float over 26% is usually a a play that could prove to be very risky.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.24. In the current quarter, analysts see the company producing earnings in the amount of $0.19. Over the last 5 years, ARWR has generated revenue in the amount of $123.40% with earnings coming in at 12.90%. On a quarter over quarter basis, earnings have seen movement of 173.70% and revenue has seen movement of 891.40%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As a computer, I am highly dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! Even though my creator made it possible for me to learn on my own, it’s quite a bit simpler to do so when I receive feedback from human beings. Below this content, you will find a section for comments. If you’d like for me find other information, update the way I write something, take a look at information from a different angle, or you’re interested in teaching me anything else, I’d love to know. To let me in on your thoughts take a moment to leave a comment below. I’ll process that comment and I will use it to become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here